Publications by authors named "C Garnacho"
Article Synopsis
- Obesity is a chronic disease marked by excess fat, leading to low-grade inflammation that promotes the release of proinflammatory substances, which can contribute to cancer development and progression.
- Proinflammatory molecules, like those released during obesity, attract immunosuppressive cells called myeloid-derived suppressor cells (MDSCs) to tumors, which are linked to worse cancer outcomes.
- The review analyzes how obesity-related MDSCs affect cancer in research and patients, highlights leptin's role in enhancing MDSC activity, and discusses therapeutic options aimed at targeting these cells in obesity-associated cancer.
Article Synopsis
- - Cancer remains a challenging and deadly disease, with traditional treatments like chemotherapy, radiotherapy, and surgery improving survival rates but facing issues like tumor progression and drug resistance.
- - Immunotherapy has gained attention as a promising new approach that leverages the immune system to fight cancer, showing positive results in both laboratory and clinical settings.
- - The integration of nanoparticles with immunotherapy is being explored to enhance immune cell access to tumors and improve treatment effectiveness, highlighting the potential of nanomedicine in cancer care.
Breast cancer (BC) continues to be the most diagnosed tumor in women and a very heterogeneous disease both inter- and intratumoral, mainly given by the variety of molecular profiles with different biological and clinical characteristics. Despite the advancements in early detection and therapeutic strategies, the survival rate is low in patients who develop metastatic disease. Therefore, it is mandatory to explore new approaches to achieve better responses.
View Article and Find Full Text PDFEnzyme replacement is a viable treatment for diseases caused by genetic deficiency of lysosomal enzymes. However, suboptimal access of enzymes to target sites limits this strategy. Polymer nanocarriers (NCs) coated with antibody against intercellular adhesion molecule 1 (ICAM-1), a protein overexpressed on most cells under disease states, enhanced biodistribution and lysosomal delivery of these therapeutics.
View Article and Find Full Text PDFAcid sphingomyelinase deficiency in type B Niemann-Pick disease leads to lysosomal sphingomyelin storage, principally affecting lungs, liver, and spleen. Infused recombinant enzyme is beneficial, yet its delivery to the lungs is limited and requires higher dosing than liver and spleen, leading to potentially adverse reactions. Previous studies showed increased enzyme pulmonary uptake by nanocarriers targeted to ICAM-1, a protein overexpressed during inflammation.
View Article and Find Full Text PDF